Biomet announced its earnings before competitors, Stryker and Zimmer, whose stocks rose in value after Biomet’s earnings were released.
Biomet’s saw some decrease in hip and knee sales, with hip sales increasing by 10 percent and knee sales by 9 percent.
Growth in the sector is expected to experience "modest deceleration," according to the report.
Read the Wall Street Journal‘s report on the Biomet quarterly earnings.
